<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20180205038619N5</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-11-21</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Effect of Botulinum toxin in traetment of neuropathy in patients with cancer</public_title>
      <acronym></acronym>
      <scientific_title>Efficacy of Botulinum Toxin in Managing Chemotherapy-Induced Pain and Paresthesia in Patients with Cancer</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-08-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>38</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/93109</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Following successful screening and the signing of an informed consent form, eligible participants will be randomly assigned to either the intervention group (receiving a subcutaneous injection of Dysport®) or the control group (receiving the medication only).
Allocation will be performed using variable-sized blocks (ranging from 4 to 6) with a 1:1 ratio to ensure balance between the groups throughout the study. The randomization sequence will be generated by an independent statistician (external to the study execution team) using the R software (via the `blockrand` package). To prevent bias during the recruitment and allocation process, a sealed-envelope method will be employed. Each study enrollment number is linked to a unique code, which is stored in an encrypted file. Once a participant is confirmed as eligible, the corresponding code will be revealed by an independent third party (distinct from the screening team, the injector, and the assessor), Blinding description: This study will be conducted as a single-blind study. The outcome assessor, who will collect the questionnaires and record the data, will be blinded to the participants’ group allocation (intervention or control). Blinding of the participants and the physician administering the injections will not be possible due to the nature of the intervention.</study_design>
      <phase>N/A</phase>
      <hc_freetext>cancer.</hc_freetext>
      <i_freetext>Intervention 1: In the intervention group, patients receive duloxetine along with subcutaneous injections of Dysport®. The total dose of Dysport is 300 units in 3 mL of normal saline (a concentration of 100 units/mL), administered in a single session via subcutaneous injections into painful areas on the palms or soles. The injections are performed using a 32-gauge needle, following a grid pattern with 1 to 2 cm spacing. Prior to the injections, 2% lidocaine gel is applied to the site for 3 minutes. Intervention 2: Patients in the control and intervention groups receive duloxetine at a daily dose of 30 mg for 24 weeks.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is no further information is available</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Katayoun Moradi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Sattarkhan</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1445613131</zip>
        <telephone>+98 21 64351</telephone>
        <email>katayounmoradi69@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mahdiye Ijadi Nasrabadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Firoozgar Hospital, Beh Afarin St, Valiasr Square</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1593748711</zip>
        <telephone>+98 21 8214 1000</telephone>
        <email>mahdieh74@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Adults aged 18 to 75 years with histopathologically confirmed cancer
A history of receiving at least one course of chemotherapy containing a taxane (such as paclitaxel or docetaxel) or a platinum-based agent (such as cisplatin, carboplatin, or oxaliplatin); at least 6 months must have elapsed since the last dose of neurotoxic chemotherapy (taxane or platinum-based agent), and the patient must not currently be receiving neurotoxic chemotherapy.
Confirmation of neuropathic pain with a DN4 score ≥ 4.
Distal and symmetrical symptoms (in the hands and/or feet) accompanied by positive sensory symptoms (paresthesia, allodynia, painful dysesthesia), confirmed through a clinical examination by a specialist in physical medicine and rehabilitation, as well as by EMG-NCS.
The symptoms must have begun during the chemotherapy itself, or at most within 6 months thereafter, and must have persisted for at least 1 month.
Stable dosage of medications for neuropathic pain (such as duloxetine or gabapentinoids) from at least 3 weeks prior to the start of the study through the end of week 24.
Ability to understand the study process and sign informed consent</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>75 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Neuropathies resulting from non-chemotherapy-related causes (e.g., neuropathy associated with uncontrolled diabetes, vitamin B12 deficiency, HIV-associated neuropathy), radiculopathy, or central pain syndromes.
Prior receipt of botulinum toxin (any serotype) within the past 6 months, or a known hypersensitivity to the components of BoNT.
Neuromuscular junction disorders (e.g., myasthenia gravis, Lambert-Eaton syndrome), clinically significant generalized weakness.
Current use of systemic corticosteroids or immunosuppressive drugs.
Pregnancy/Breastfeeding
Active infection, uncontrolled lymphedema, or skin damage in the limbs intended for injection.
Planning for the initiation or modification of systemic medications for CIPN during the study.
Coagulation disorders (platelet count &lt; 75 × 10⁹/L) or anticoagulant therapy that cannot be safely discontinued for the purpose of administering injections.
Life expectancy &lt;12 months due to cancer recurrence or other comorbidities.
Cognitive impairment that prevents responding to questionnaires</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>In the intervention group, patients receive duloxetine along with subcutaneous injections of Dysport®. The total dose of Dysport is 300 units in 3 mL of normal saline (a concentration of 100 units/mL), administered in a single session via subcutaneous injections into painful areas on the palms or soles. The injections are performed using a 32-gauge needle, following a grid pattern with 1 to 2 cm spacing. Prior to the injections, 2% lidocaine gel is applied to the site for 3 minutes.</i_keyword>
      <i_keyword>Patients in the control and intervention groups receive duloxetine at a daily dose of 30 mg for 24 weeks.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain intensity. Timepoint: base, 4w, 12w, 24w. Method of measurement: self reported/ NRS.</prim_outcome>
      <prim_outcome>Paresthesia intensity. Timepoint: base, 4w, 12w, 24w. Method of measurement: Neuropathic Pain Symptom Inventory(NPSI) questoinnere.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-05-14</approval_date>
        <contact_name>research ethics committees of school of medicine</contact_name>
        <contact_address>hemmat highway TEHRAN Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
